21st Nov 2019 18:55
(Alliance News) - MaxCyte Inc on Thursday said it has signed a clinical and commercial license agreement with oncology business Vor Biopharma.
Under the agreement, Vor will use MaxCyte's Flow Electroporation technology to produce engineered hematopoietic stem cells - hematopoietic stem cells being those that become blood cells - and to initiate studies aimed at an investigational new drug application.
Vor has non-exclusive clinical and commercial rights to life science company MaxCyte's Flow Electroporation technology and its ExPERT platform in order to develop as many as five engineered cell therapies. This includes Vor's lead engineered hematopoietic stem cell candidate, VOR33, which is intended to treat acute myeloid leukemia.
Doug Doerfler, president & chief executive of MaxCyte, said: "We look forward to expanding our relationship with Vor Biopharma as the company pioneers a potential future standard of care in hematopoietic stem cell transplants for cancer patients in need.
"This agreement represents another key business milestone for MaxCyte, emphasizing the value of our technology platform applied to next-generation engineered cell therapies that may make a true difference in patient outcomes."
By Anna Farley; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
MaxCyte